Description

Dasiglucagon acetate (CAS No. 1544300-84-6), also known as ZP-4207, is a synthetic peptide analog of human glucagon. It is designed to be more stable and soluble in aqueous solutions compared to native glucagon, making it suitable for various research applications. Dasiglucagon acetate functions by binding to glucagon receptors, leading to increased plasma glucose levels, which is particularly useful in hypoglycemia research.

This compound has potential applications in the study of severe hypoglycemia, especially in the context of diabetes management. Dasiglucagon acetate is manufactured under GMP standards with a purity of 99.92%, ensuring consistency and reliability for experimental use.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action:
Dasiglucagon acetate operates through the same mechanism as endogenous glucagon, acting as an agonist at glucagon receptors expressed throughout the body. Binding to liver glucagon receptors activates adenylate cyclase, increasing intracellular cyclic AMP levels, which stimulates glycogenolysis and gluconeogenesis in the liver, leading to elevated blood glucose levels.

Research Applications:

• Hypoglycemia Studies: Investigating treatments for severe hypoglycemia, particularly in diabetic patients.

• Diabetes Research: Exploring the role of glucagon analogs in glucose metabolism and insulin regulation.

  

Side Effects (Research Context Only)

Dasiglucagon acetate is intended for laboratory research use only. In preclinical studies, it has been shown to increase plasma glucose levels without significant adverse effects. However, as with all experimental compounds, appropriate safety protocols should be followed during handling and administration.

Disclaimer

Dasiglucagon acetate is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Users should adhere to institutional safety guidelines and regulatory requirements when handling this compound.